Trending...
- RAS AP Consulting Expands Managed AP Governance™ Ecosystem, Launches Trademark Process, and Secures IFOL Speaker Invitation
- UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
- FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
CHAPEL HILL, N.C., June 21, 2024 ~ The International Society on Thrombosis and Haemostasis (ISTH) has recently released a groundbreaking clinical practice guideline for the treatment of congenital hemophilia A and B. This guideline, developed over several years by a multidisciplinary panel of physicians and patient representatives from around the world, utilizes strict GRADE methodology to provide a rigorous and structured decision-making framework for clinicians, healthcare professionals, patients, and their caregivers.
Hemophilia is a rare bleeding disorder caused by deficiencies in blood coagulation factors. It affects hundreds of thousands of individuals worldwide and requires complex management strategies. The objective of this guideline is to offer a comprehensive overview of evidence to help inform treatment decisions.
The panel prioritized key clinical questions and outcomes crucial for both clinicians and patients. The recommendations underwent rigorous analyses, including public commentary, to ensure comprehensiveness, transparency, and inclusivity. The result is a set of 13 recommendations addressing critical aspects of hemophilia A and B care.
More on ncarol.com
One of the most significant recommendations advocates for prophylactic treatment over episodic interventions for severe and moderately severe hemophilia A and B. This marks a paradigm shift in clinical practice as it emphasizes the importance of preventing bleeds rather than treating them after they occur.
Dr. Suely M. Rezende, Chair of the ISTH Hemophilia Guideline Panel, stated that "with hemophilia management being complex, our guideline provides clarity, guiding treatment decisions with evidence-based insight while highlighting the importance of considering individual risks, values, and preferences."
To provide further guidance on the interpretation and implementation of the guideline, commentaries have been published alongside it by preeminent experts in the field. These commentaries also address challenges for clinical practice and policy related to hemophilia treatment.
More on ncarol.com
The new guideline also addresses important gaps in scientific data and identifies critical research priorities. As new treatments become available in the ever-evolving landscape of hemophilia care, future updates to the guideline are expected to encompass these advancements.
The ISTH remains committed to advancing hemophilia research and improving the lives of people with hemophilia worldwide. By continuously updating and complementing this guideline, they aim to drive innovation and enhance outcomes for individuals living with this rare disease.
For more information and to access the full guideline and accompanying commentaries, please visit https://www.isth.org/page/hemophiliaguideline. This comprehensive resource provides valuable insights into the evolving hemophilia treatment landscape and emphasizes the importance of patient involvement and shared decision-making in treatment decisions.
Hemophilia is a rare bleeding disorder caused by deficiencies in blood coagulation factors. It affects hundreds of thousands of individuals worldwide and requires complex management strategies. The objective of this guideline is to offer a comprehensive overview of evidence to help inform treatment decisions.
The panel prioritized key clinical questions and outcomes crucial for both clinicians and patients. The recommendations underwent rigorous analyses, including public commentary, to ensure comprehensiveness, transparency, and inclusivity. The result is a set of 13 recommendations addressing critical aspects of hemophilia A and B care.
More on ncarol.com
- Crossroads4Hope Marks 25 Years Ensuring No One Faces Cancer Alone At its Inspiring Hope Gala
- Q1 2026 Arizona Technology Industry Impact Report Recaps Advanced Manufacturing Growth, High-Value Jobs and Workforce Investment
- Former Prosecutor Opens Stegall Law in Summerville
- Vboost Celebrates 14 years of Automotive Viral Marketing
- EXETR Exteriors Unveils XOS — Proprietary Roofing Project Management Platform
One of the most significant recommendations advocates for prophylactic treatment over episodic interventions for severe and moderately severe hemophilia A and B. This marks a paradigm shift in clinical practice as it emphasizes the importance of preventing bleeds rather than treating them after they occur.
Dr. Suely M. Rezende, Chair of the ISTH Hemophilia Guideline Panel, stated that "with hemophilia management being complex, our guideline provides clarity, guiding treatment decisions with evidence-based insight while highlighting the importance of considering individual risks, values, and preferences."
To provide further guidance on the interpretation and implementation of the guideline, commentaries have been published alongside it by preeminent experts in the field. These commentaries also address challenges for clinical practice and policy related to hemophilia treatment.
More on ncarol.com
- Ignazio Arces Wins Stevie® Award for Maverick of the Year at the 2026 International Business Awards
- New from Regal House, The Great Awakening: dark comic vision of a split nation veering off the rails
- Tickeron Highlights AI Trading Agent Performance Across Multiple Market Sectors
- Stop Bleeding Cash on Mediocre Talent. Build a Powerhouse Remote Team Instead
- Crownlight Strategies® Announces Federal Trademark Registration
The new guideline also addresses important gaps in scientific data and identifies critical research priorities. As new treatments become available in the ever-evolving landscape of hemophilia care, future updates to the guideline are expected to encompass these advancements.
The ISTH remains committed to advancing hemophilia research and improving the lives of people with hemophilia worldwide. By continuously updating and complementing this guideline, they aim to drive innovation and enhance outcomes for individuals living with this rare disease.
For more information and to access the full guideline and accompanying commentaries, please visit https://www.isth.org/page/hemophiliaguideline. This comprehensive resource provides valuable insights into the evolving hemophilia treatment landscape and emphasizes the importance of patient involvement and shared decision-making in treatment decisions.
Filed Under: Business
0 Comments
Latest on ncarol.com
- Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community
- Lineus Medical Elevates Leadership to Accelerate Growth After Breakthrough Clinical Results
- Gateway Center Arena Announces Duane Curry as General Manger
- New from Regal House Publishing, The Parliament of Mice, classic animal fables retold as satires
- XRPPower Expands Platform Security With Enhanced Brand Protection and Official Verification Standards
- Cuvo Health, the #1 White Label Telehealth Platform, Surpasses 300 Exclusive Providers Serving All 50 States
- RAS AP Consulting Expands Managed AP Governance™ Ecosystem, Launches Trademark Process, and Secures IFOL Speaker Invitation
- UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
- International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea
- The City's Most Elegant Open-Air Dinner Party Returns September 12, 2026
- FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
- Autonomous Robotics Platform Expansion as Public Market Debut is Very Close: MBody AI Corp. (N A S D A Q: MBAI)
- New Book gives Consumer Goods Leaders a Governance Playbook for Generative and Agentic AI
- Loud! OOH calls for prize draw advertising standards as £1.3bn category moves outdoors
- Black Ribbon Productions Launches With Fearless 2026 Horror Slate
- Actor Dominic Pace Returns to Television and Film
- Opteamix welcomes Girish Ramachandra to its leadership team as Senior Vice President of Client Services
- Silicon Box Ships 500M Units at High Yield, Expands Production Capacity for Panel-Level Packaging
- Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home
- RPR Promotes Emily Line to Chief Strategy Officer and Janine Sieja to Chief Product Officer